Restaging Transurethral Resection for Non-Muscle Invasive Bladder Cancer. Who, Why, When, and How?

Urologic Clinics of North America

Volumn 40, Issue 2, 2013, Pages 295-304

  Ritch, Chad R ^a   Clark, Peter E ^a   Morgan, Todd M ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Non muscle invasive bladder cancer; Repeat resection; Restaging; Second look cystoscopy; Transurethral resection; Understaging; Upstaging

Indexed keywords

AMINOLEVULINIC ACID; BCG VACCINE; MITOMYCIN;

CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARCINOMA IN SITU; CLINICAL EFFECTIVENESS; CYSTECTOMY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; HUMAN; HYDRONEPHROSIS; NON MUSCLE INVASIVE BLADDER CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION OF BLADDER TUMOR; TUMOR VOLUME; UROGENITAL TRACT CANCER;

CYSTECTOMY; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84876705087     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2013.01.009     Document Type: Review

References (64)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. David K.A., Mallin K., Milowsky M.I., et al. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer 2009, 115:1435-1447.
3. Lopez-Beltran A., Montironi R. Noninvasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004, 46:170-176.
4. Donat S.M. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003, 30:765-776.
5. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001, 19:666-675.
6. Freedman N.D., Silverman D.T., Hollenbeck A.R., et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011, 306:737-745.
7. Rink M., Xylinas E., Babjuk M., et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol 2012, 188:2120-2128.
8. Lammers R.J., Witjes W.P., Hendricksen K., et al. Smoking status is a risk factor for recurrence after transurethral resection of nonmuscle-invasive bladder cancer. Eur Urol 2011, 60:713-720.
9. Garcia-Closas M., Malats N., Silverman D., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005, 366:649-659.
10. Divrik R.T., Sahin A.F., Yildirim U., et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010, 58:185-190.
11. Samaratunga H., Makarov D.V., Epstein J.I. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 2002, 60:315-319.
12. Pan C.C., Chang Y.H., Chen K.K., et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of nonmuscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol 2010, 133:788-795.
13. Leblanc B., Duclos A.J., Benard F., et al. Long-term follow-up of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 1999, 162:1946-1950.
14. Herr H.W. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000, 163:60-61. [discussion: 61-2].
15. Cheng L., Neumann R.M., Weaver A.L., et al. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999, 17:3182-3187.
16. Holmang S., Hedelin H., Anderstrom C., et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997, 157:800-803. [discussion: 4].
17. Bernardini S., Billerey C., Martin M., et al. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol 2001, 165:42-46. [discussion: 6].
18. Miyamoto H., Epstein J.I. Transurethral resection specimens of the bladder: outcome of invasive urothelial cancer involving muscle bundles indeterminate between muscularis mucosae and muscularis propria. Urology 2010, 76:600-602.
19. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-477. [discussion: 75-7].
20. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000, 163:73-78.
21. Lamm D.L. Carcinoma in situ. Urol Clin North Am 1992, 19:499-508.
22. Divrik R.T., Sahin A., Altok M., et al. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. J Urol 2007, 178:802-806. [discussion: 6].
23. Kamat A.M., Gee J.R., Dinney C.P., et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006, 175:881-885.
24. Cho K.S., Seo H.K., Joung J.Y., et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 2009, 182:2625-2630.
25. Resnick M.J., Bergey M., Magerfleisch L., et al. Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJU Int 2011, 107:46-52.
26. Cordon-Cardo C., Zhang Z.F., Dalbagni G., et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997, 57:1217-1221.
27. Hitchings A.W., Kumar M., Jordan S., et al. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br J Cancer 2004, 91:552-557.
28. Sanchez-Carbayo M., Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol 2007, 34:75-84.
29. Hall M.C., Chang S.M., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1 and Tis): 2007 update. J Urol 2007, 178(6):2314-2330.
30. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59:997-1008.
31. Dalbagni G., Vora K., Kaag M., et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009, 56:903-910.
32. Kulkarni G.S., Hakenberg O.W., Gschwend J.E., et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010, 57:60-70.
33. Dutta S.C., Smith J.A., Shappell S.B., et al. Clinical under staging of high-risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001, 166:490-493.
34. Weizer A.Z., Wasco M.J., Wang R., et al. Multiple adverse histological features increase the odds of under staging T1 bladder cancer. J Urol 2009, 182:59-65. [discussion: 65].
35. Bianco F.J., Justa D., Grignon D.J., et al. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004, 22:290-294.
36. Gupta A., Lotan Y., Bastian P.J., et al. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 2008, 71:302-307.
37. Mariappan P., Zachou A., Grigor K.M., et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010, 57:843-849.
38. Badalato G., Patel T., Hruby G., et al. Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer?. BJU Int 2011, 108:1292-1296.
39. Huguet J., Crego M., Sabate S., et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005, 48:53-59. [discussion: 9].
40. Fritsche H.M., Burger M., Svatek R.S., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010, 57:300-309.
41. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999, 162:74-76.
42. Schwaibold H.E., Sivalingam S., May F., et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006, 97:1199-1201.
43. Schips L., Augustin H., Zigeuner R.E., et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?. Urology 2002, 59:220-223.
44. Herr H.W., Donat S.M. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006, 97:1194-1198.
45. Nieder A.M., Manoharan M. The role of the surgeon and transurethral resection in the treatment of superficial bladder cancer. ScientificWorldJournal 2006, 6:2626-2631.
46. Han K.S., Joung J.Y., Cho K.S., et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol 2008, 22:2699-2704.
47. Herr H.W. Restaging transurethral resection of high-risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005, 174:2134-2137.
48. Guevara A., Salomon L., Allory Y., et al. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer. J Urol 2010, 183:2161-2164.
49. Divrik R.T., Yildirim U., Zorlu F., et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006, 175:1641-1644.
50. Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004, 171:2186-2190. [quiz: 435].
51. Herr H.W. Is repeat transurethral resection needed for minimally invasive T1 urothelial cancer? Pro. J Urol 2011, 186:787-788.
52. Grimm M.O., Steinhoff C., Simon X., et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003, 170:433-437.
53. Dalbagni G., Herr H.W., Reuter V.E. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 2002, 60:822-824. [discussion: 824-5].
54. Kulkarni G.S., Urbach D.R., Austin P.C., et al. Longer wait times increase overall mortality in patients with bladder cancer. J Urol 2009, 182:1318-1324.
55. Herr H.W., Donat S.M. Quality control in transurethral resection of bladder tumours. BJU Int 2008, 102:1242-1246.
56. Balbay M.D., Cimentepe E., Unsal A., et al. The actual incidence of bladder perforation following transurethral bladder surgery. J Urol 2005, 174:2260-2262. [discussion: 2262-3].
57. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002, 41:523-531.
58. Kriegmair M., Baumgartner R., Knuechel R., et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994, 44:836-841.
59. Grossman H.B., Stenzl A., Fradet Y., et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012, 188:58-62.
60. Inoue K., Fukuhara H., Shimamoto T., et al. Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. Cancer 2012, 118:1062-1074.
61. Kausch I., Sommerauer M., Montorsi F., et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010, 57:595-606.
62. Karaolides T., Skolarikos A., Bourdoumis A., et al. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?. Urology 2012, 80:354-359.
63. Weizer A.Z., Wasco M.J., Wang R., et al. Multiple adverse histological features increase the odds of under staging T1 bladder cancer. J Urol 2009, 182(1):59-65.
64. Ficarra V., Dalpiaz O., Alrabi N., et al. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 2005, 95(6):786-790.